Sarepta Pops on More Positive Data


Shares of development-stage biotech Sarepta Therapeutics popped 4.3% today after the company released data from the extension phase of its phase 2b clinical study for its Duchenne muscular dystrophy drug eteplirsen. Like most stocks in this space, Sarepta faces a number of risks; eteplirsen, for instance, is the company's main asset, and any setbacks to its development, regulatory delays, or safety issues could make shares plunge. Also, Sarepta is running a very small clinical trial and it may not be able to file for accelerated approval. However, to date, the drug has displayed a clean safety profile and continues to show efficacy. In the following video, health-care analyst Max Macaluso discusses these topics and what today's news means for investors.

It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long-term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today

The article Sarepta Pops on More Positive Data originally appeared on

Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published